NCT03136809 is a Phase 1, PHASE2 clinical trial of Cu(II)ATSM in Amyotrophic Lateral Sclerosis, sponsored by Collaborative Medicinal Development Pty Limited.

Who is sponsoring NCT03136809?

NCT03136809 is sponsored by Collaborative Medicinal Development Pty Limited.

What drugs are being tested in NCT03136809?

Interventions in NCT03136809: Cu(II)ATSM.

What condition does NCT03136809 study?

NCT03136809 studies Amyotrophic Lateral Sclerosis.

Is NCT03136809 still recruiting?

NCT03136809 is currently status unknown. Last updated 17 February 2022.

Last reviewed 2022-02-17 · How we verify

NCT03136809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALS Treatment Extension Study

Status unknown Phase 1, PHASE2 Last updated 17 February 2022

What this trial tests

Phase 1, PHASE2 trial testing Cu(II)ATSM in Amyotrophic Lateral Sclerosis in 28 participants. Status unknown.

Timeline

18 January 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Collaborative Medicinal Development Pty Limited
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	18 January 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Australia

Drugs / interventions tested

Cu(II)ATSM — full drug profile →

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

Collaborative Medicinal Development Pty Limited — full company profile →

Who can join

Adults 18 to 75, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular mechanisms of cell death in neurological diseases.
Moujalled D, Strasser A, Liddell JR. · · 2021 · cited 513× · PMID 34099897 · DOI 10.1038/s41418-021-00814-y
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease.
Nguyen TT, Wei S, Nguyen TH, Jo Y, et al · · 2023 · cited 221× · PMID 37612409 · DOI 10.1038/s12276-023-01046-5
Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic.
Trist BG, Hilton JB, Hare DJ, Crouch PJ, et al · · 2021 · cited 148× · PMID 32144830 · DOI 10.1002/anie.202000451
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?
Liddell JR. · · 2017 · cited 114× · PMID 28820437 · DOI 10.3390/antiox6030065
Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons Using Calcium Phosphate-Lipid Nanoparticles.
Chen L, Watson C, Morsch M, Cole NJ, et al · · 2017 · cited 49× · PMID 28912673 · DOI 10.3389/fnins.2017.00476
Cu<sup>II</sup>(atsm) Attenuates Neuroinflammation.
Choo XY, Liddell JR, Huuskonen MT, Grubman A, et al · · 2018 · cited 22× · PMID 30319344 · DOI 10.3389/fnins.2018.00668
Astrocytes: Dissecting Their Diverse Roles in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Valori CF, Sulmona C, Brambilla L, Rossi D. · · 2023 · cited 21× · PMID 37296571 · DOI 10.3390/cells12111450
CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis.
Dennys CN, Roussel F, Rodrigo R, Zhang X, et al · · 2023 · cited 15× · PMID 36213964 · DOI 10.1002/glia.24278

Verify or expand the search:

Other trials of Cu(II)ATSM

Trials testing the same drug.

NCT04313166 — Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 · Phase 2 · completed
NCT04082832 — CuATSM Compared With Placebo for Treatment of ALS/MND · Phase 2, PHASE3 · unknown
NCT03204929 — Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease · Phase 1 · completed
NCT02870634 — Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND · Phase 1 · completed

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other Collaborative Medicinal Development Pty Limited trials

Trials by the same sponsor.

NCT04313166 — Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 · Phase 2 · completed
NCT04082832 — CuATSM Compared With Placebo for Treatment of ALS/MND · Phase 2, PHASE3 · unknown
NCT03204929 — Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease · Phase 1 · completed
NCT02870634 — Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND · Phase 1 · completed
NCT02688101 — Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03136809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Collaborative Medicinal Development Pty Limited
Last refreshed: 17 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03136809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing